PEB
23/10/2015 16:29
GENERAL
NOT PRICE SENSITIVE
REL: 1629 HRS Pacific Edge Limited
GENERAL: PEB: PE Ends Commercial Partnership with Healthscope in AU
23 October 2015
Pacific Edge Ends Commercial Partnership with Healthscope in Australia
Following a indepth review of its progress in Australia, Pacific Edge Limited
(NZX:PEB) has announced it is ending its agreement with Healthscope and
looking to finalise the selection and negotiation with a new commercial
partner to market and distribute its innovative Cxbladder bladder cancer
diagnostic tests.
Australia remains a small but real market for Pacific Edge, with
approximately 3,000 Australians estimated to have bladder cancer in 2015 ,
compared to more than half million in the USA , the company's primary market.
CEO of Pacific Edge, David Darling, said: "We have had a long standing
relationship with Healthscope and they have been a supportive partner while
we bought our first two Cxbladder tests to market. We are now looking to
finalise the selection and negotiation with a new commercial partner who will
work with our team in New Zealand and our Melbourne based in-country manager
to drive sales and encourage clinical use of Cxbladder. We expect these
negotiations to be concluded in the near term."
Cxbladder tests for Australian patients will continue to be processed in
Pacific Edge's certified laboratory in New Zealand, providing a fast and
efficient turnaround on results.
ENDS
For more information contact:
David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800
GENERAL OVERVIEW
www.pacificedge.co.nz
www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer
diagnostic company specialising in the discovery and commercialisation of
diagnostic and prognostic tests for better detection and monitoring of
cancer. The company is developing and commercialising its range of Cxbladder
bladder cancer tests globally through its wholly owned central laboratories
in New Zealand and the USA. The company's products have been tested and
validated in international multi-centre clinical studies.
PRODUCTS
Pacific Edge has two proprietary, novel, accurate, molecular diagnostic
products in-market providing more accurate, and better detection and
management of urothelial cancer. Cxbladder Detect is available through the
company's dedicated CLIA certified laboratories for customers in New Zealand,
Australia and the USA. Cxbladder Triage is available in New Zealand and
Australia and will launch in the USA in 2015.
ABOUT Cxbladder Triage
www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with extra
phenotypic and clinical risk factors to accurately identify and remove
patients with haematuria who have a low probability of bladder cancer, from
requiring a full-urological work-up. Cxbladder Triage is a tool for use by
clinicians and physicians in primary evaluation and is intended to reduce of
the number of patients needing an expensive and invasive work-up for
urothelial cancer.
ABOUT Cxbladder Detect
www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other
urinary tract cancers from a small volume of a patients' urine. Cxbladder
Detect was launched in 2013 in the USA and is commercially available in New
Zealand, Australia and the USA as a Laboratory Developed Test (LDT) from the
company's CLIA certified laboratories. Cxbladder Detect provides physicians
and clinicians with a quick, cost effective and accurate measure of the
presence of the cancer as an effective adjunct to cystoscopy.
Refer to www.cxbladder.com for more information.
End CA:00272279 For:PEB Type:GENERAL Time:2015-10-23 16:29:09
